MAD2L1 and cancer: In conclusion, this review illustrates the potential for MAD2 IHC as a prognostic biomarker in cancer, especially in ovarian cancer where there is approximately a 50% lower risk of death or tumour recurrence in patients in the higher MAD2 expression category compared to the lower.